[Skip to Content]
[Skip to Content Landing]
Views 1,931
Citations 0
Viewpoint
September 2016

Cardiovascular Monitoring With Trastuzumab TherapyHow Frequent Is Too Frequent?

Author Affiliations
  • 1Rush Medical College, Chicago, Illinois
  • 2Section of Medical Oncology, Rush University Medical Center, Chicago, Illinois
  • 3Division of Cardiology, Rush University Medical Center, Chicago, Illinois
JAMA Oncol. 2016;2(9):1123-1124. doi:10.1001/jamaoncol.2016.1288

Trastuzumab has led to meaningful improvements in survival in early-stage and metastatic ERBB2 (formerly HER2 or HER2/neu)-positive breast cancer.1,2 Trastuzumab is generally well tolerated but is associated with infrequent cardiac dysfunction, manifested most often as an asymptomatic decline in left ventricular ejection fraction (LVEF).16

First Page Preview View Large
First page PDF preview
First page PDF preview
×